Financial Daily from THE HINDU group of publications
Friday, Apr 02, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements


Orchid's anti-diabetic molecule clears clinical trials

Our Bureau

Chennai , April 1

ORCHID Chemicals & Pharmaceuticals Ltd on Thursday said an anti-diabetic molecule that its US joint venture Bexel Pharmaceuticals Inc has been working on, has cleared clinical trials for toxicity and safety levels in Europe.

In a press release, the Orchid's Managing Director, Mr K. Raghavendra Rao, expressed confidence that the molecule, BLX-1002, would be licensed to manufacturers after more advanced stages of clinical trials in May.

It has generated good enquiries and the company will start negotiating with multinationals at the appropriate time.

BLX-1002 is a novel, orally active small molecule. The toxicity and safety studies constituting Phase 1(a) carried out on 42 healthy volunteers have shown that BLX-1002 is a highly safe diabetic compound. It is safe up to 1600 mg against the anticipated human dose of 20-40 mg, the release said.

The next stage of testing, Phase 1(b), will determine safety levels at repeated doses.

More Stories on : Announcements | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Reliance, Niko find gas in K-G Basin


Godavari Fert ceases to be CFL subsidiary
Orchid's anti-diabetic molecule clears clinical trials
Continental to source tyre tubes from Metro
No clearance to ChemPlast Krishnapatnam unit
Assocham plea to abolish MAT
Bharat Petroleum announces VRS
Tata Steel, workers' union in pact for JUSCO transfer
Spanco issue
Kerala Cabinet okays Trayons promoter's revival plan
LG bullish on India; plans to triple growth
Philips India aims 100 pc growth in 5 yrs — Proposes to sell HTP unit
Tata Steel output touches 4 million tonnes
Hero Honda sales cross two-million mark in a year
MMTC Singapore arm posts record turnover — Makes foray into sophisticated, competitive markets
Maruti sales rise 30 pc in 2003-04
HPC, subsidiary post Rs 870-cr combined turnover
Bajaj Auto sales rise 26 pc
BEML posts Rs 1,771-cr sales turnover
TVS Motor sales grow at 2.5 pc
Ford India scores record sales in March
HAL registers record turnover at Rs 3,690 cr
New VSP Director
Coke gets reprieve in Kerala



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line